Lupin Receives U.S. Approval for Diazepam Injection
Lupin Limited announced on July 28, 2026, that it has received U.S. approval for its Diazepam Injection, USP. The approval was granted under the Federal Food, Drug, and Cosmetic Act.
Global pharmaceutical company Lupin Limited announced on July 28, 2026, that it has secured approval from the U.S. Food and Drug Administration (FDA) for its Diazepam Injection, USP. This approval, granted under the Federal Food, Drug, and Cosmetic Act, permits Lupin to manufacture and market the injectable form of diazepam in the United States. Diazepam is commonly used to treat anxiety, muscle spasms, and seizures.
The approval signifies Lupin's continued expansion in the U.S. market, a key focus for the company's growth strategy. This product will add to Lupin's existing portfolio of generic and specialty medicines. The company operates in several therapeutic areas, including central nervous system disorders.
Lupin, which has a significant global footprint, focuses on developing and commercializing a wide range of pharmaceutical products. The U.S. pharmaceutical market is one of the largest in the world, and gaining regulatory approval for new products is crucial for sustained market presence.
Further details regarding the launch timeline and commercialization plans for Diazepam Injection, USP in the United States were not immediately available.